Benzinga | May 12, 2021 12:47PM EDT

MedTech Round Up: Update On Lucira Health, Second Sight Medical ClearPoint Neuro, Medtronic, Sientra

Lucira Health Inc (NASDAQ: LHDX) has announced that its Lucira Check IT COVID-19 test kit is now available on Amazon.com in the US.

* Each Lucira Check IT test kit provides a PCR quality test result at home in 30 minutes or less. The product costs $55.

* Price Action: LHDX shares are trading 14.3% higher at $5.82 during the market session on the last check Wednesday.



Second Sight Medical Products Inc (NASDAQ: EYES) has announced two-year results of its Early Feasibility Study of the Orion Visual Cortical Prosthesis.

* Data showed that all five patients tested at the two-year mark could locate a white square on a dark computer screen significantly better with the Orion System on than with it off.

* 4/5 were able to identify better the direction of motion of a bar moving across a computer screen.

* Orion is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes.

* Price Action: EYES shares are trading 43.6% higher at $7.18 during the market session on the last check Wednesday.



ClearPoint Neuro Inc (NASDAQ: CLPT) announced FDA clearance for its SmartFrame Array, a navigation system designed for use in both the MRI suite and operating room.

* The company reported Q1 sales of $4.03 million, which beat the analyst consensus estimate of $3.27 million, and up 29% Y/Y.

* It sees sales in the range of $16-$17.5 million for the 2021 calendar year, better than the consensus of $15.83 million.

* Price Action: CLPT shares are trading 1.67% higher at $17.96 during the premarket session on the last check Wednesday.



Medtronic Plc (NYSE: MDT) is recalling HeartWare HVAD System to provide updated Instructions due to safety issues with Carrying Cases, Driveline Cover Orientation, and Controller Power-Up Sequence.

* HVAD System helps the heart continue to pump blood to the rest of the body.

* The faulty devices may cause serious patient harm, including death.

* There have been one death and 64 injuries reported to the FDA for these issues.

* Price Action: MDT shares are trading 1.56% lower at $123.27 during the market session on the last check Wednesday.



Sientra Inc (NASDAQ: SIEN) has agreed to sell its miraDry business to 1315 Capital, a healthcare growth equity firm. Deal terms were not disclosed.

* The miraDry system provides a non-invasive treatment that offers a lasting solution for underarm sweat.

* It reported Q1 2021 sales of $23.2 million, a 37% Y/Y increase and beating the consensus estimate of $18.8 million.

* Sientra sees full-year 2021 breast products sales in the range of $72 to $76 million, representing 31%-38% growth Y/Y, compared to previous guidance of $70 million to $74 million.

* Price Action: SIEN shares are trading 5.3% lower at $6.38 during the market session on the last check Wednesday.